These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 8316763)

  • 21. Correlation between plasma glucocorticoids and clinical outcomes in living-related renal transplant recipients.
    Shibata N; Ohmae T; Hoshino N; Minouchi T; Yamaji A; Park KI; Tomoyoshi T; Abe H; Kodama M
    Transplant Proc; 1998 Nov; 30(7):3053-6. PubMed ID: 9838346
    [No Abstract]   [Full Text] [Related]  

  • 22. Bone histopathology and densitometry comparison between cyclosporine a monotherapy and prednisolone plus azathioprine dual immunosuppression in renal transplant patients.
    Cueto-Manzano AM; Konel S; Crowley V; France MW; Freemont AJ; Adams JE; Mawer B; Gokal R; Hutchison AJ
    Transplantation; 2003 Jun; 75(12):2053-8. PubMed ID: 12829911
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The importance of thiopurine methyltransferase activity for the use of azathioprine in transplant recipients.
    Chocair PR; Duley JA; Simmonds HA; Cameron JS
    Transplantation; 1992 May; 53(5):1051-6. PubMed ID: 1585469
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical assessment of trough levels for monitoring of rejection in cyclosporine-treated kidney transplant recipients.
    Takahara S; Namiki M; Kokado Y; Kameoka H; Okuyama A
    Int Urol Nephrol; 1996; 28(3):431-8. PubMed ID: 8899485
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative analysis of azathioprine versus cyclosporine-based therapy in primary haplo-identical live-donor kidney transplantation: a 20-year experience.
    Gheith OA; Bakr MA; Fouda MA; Shokeir AA; Sobh M; Ghoneim M
    Saudi J Kidney Dis Transpl; 2008 Jul; 19(4):564-70. PubMed ID: 18580014
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prospective randomized study of azathioprine vs cyclosporine based therapy in primary haplo-identical living-donor kidney transplantation: 20-year experience.
    Gheith OA; Bakr MA; Fouda MA; Shokeir AA; Sobh M; Ghoneim M
    Clin Exp Nephrol; 2007 Jun; 11(2):151-155. PubMed ID: 17593515
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Donor bone marrow-derived chimeric cells present in renal transplant recipients infused with donor marrow. I. Potent regulators of recipient antidonor immune responses.
    Mathew JM; Garcia-Morales R; Fuller L; Rosen A; Ciancio G; Burke GW; Carreno M; Temple D; Tzakis AG; Ricordi C; Miller J; Esquenazi V
    Transplantation; 2000 Dec; 70(12):1675-82. PubMed ID: 11152096
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term graft survival with or without donor-specific transfusion in cyclosporine era in one haplo-identical living-related renal transplant recipients beyond the first year: a 19-year experience.
    Satoh S; Sugimura J; Omori S; Seino K; Fujizuka I
    Tohoku J Exp Med; 2002 Aug; 197(4):201-7. PubMed ID: 12434995
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Donor specific transfusion in kidney transplantation: effect of different immunosuppressive protocols on graft outcome.
    Barbari A; Stephan A; Masri MA; Joubran N; Dagher O; Kamel G
    Transplant Proc; 2001 Aug; 33(5):2787-8. PubMed ID: 11498161
    [No Abstract]   [Full Text] [Related]  

  • 30. Analysis of risk factors for cutaneous warts in renal transplant recipients.
    Barba A; Tessari G; Talamini G; Chieregato GC
    Nephron; 1997; 77(4):422-6. PubMed ID: 9434064
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Optimal combination of immunosuppressive agents for renal transplantation: first report of a multicentre, randomised trial comparing cyclosporine+prednisolone with cyclosporine+azathioprine and with triple therapy in cadaver renal transplantation. The Australian Collaborative Trials Committee.
    Hardie IR; Tiller DJ; Mahony JF; Miach PJ; Thomson NM; Thatcher GN; Rigby RJ; Menzies BL
    Transplant Proc; 1993 Feb; 25(1 Pt 1):583-4. PubMed ID: 8438424
    [No Abstract]   [Full Text] [Related]  

  • 32. Determination of an improved sirolimus (rapamycin)-based regimen for induction of allograft tolerance in mice treated with antilymphocyte serum and donor-specific bone marrow.
    Hale DA; Gottschalk R; Maki T; Monaco AP
    Transplantation; 1998 Feb; 65(4):473-9. PubMed ID: 9500619
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasma (total and ionized), erythrocyte and platelet magnesium levels in renal transplant recipients during cyclosporine and/or azathioprine treatment.
    Allegra A; Corica F; Ientile R; Corsonello A; Sparacino V; Accettola F; Caputo F; Macaione S; Buemi M
    Magnes Res; 1998 Mar; 11(1):11-8. PubMed ID: 9595545
    [TBL] [Abstract][Full Text] [Related]  

  • 34. First report of an Australian randomised trial comparing cyclosporine+prednisolone with cyclosporine+azathioprine and cyclosporine+azathioprine+prednisolone in renal transplantation.
    Hardie IR; Tiller DJ; Mahony JF; Miach PJ; Thomson NM; Thatcher GN; Rigby RJ; Menzies BL
    Transplant Proc; 1992 Oct; 24(5):2241-2. PubMed ID: 1413040
    [No Abstract]   [Full Text] [Related]  

  • 35. Effect of cyclosporin A on DNA repair and cancer incidence in kidney transplant recipients.
    Herman M; Weinstein T; Korzets A; Chagnac A; Ori Y; Zevin D; Malachi T; Gafter U
    J Lab Clin Med; 2001 Jan; 137(1):14-20. PubMed ID: 11150019
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Some aspects of hemostasis in kidney transplant recipients maintained on cyclosporine, azathioprine, and prednisone in comparison to patients treated with cyclosporine and prednisone.
    Malyszko J; Malyszko JS; Hryszko T; Mysliwiec M
    Transplant Proc; 2003 Dec; 35(8):2940-2. PubMed ID: 14697944
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Infectious complications in renal transplant recipients: a 10-year review of cyclosporine-based immunosuppression.
    Tsai MK; Lee PH; Hu RH; Lee CJ
    Transplant Proc; 1998 Nov; 30(7):3125-6. PubMed ID: 9838381
    [No Abstract]   [Full Text] [Related]  

  • 38. [Study of 54 renal allograft recipients in the cyclosporin A era. What influences acute rejection episode and long-term graft survival?].
    Tanda K; Takeuchi I; Chikaraishi T; Togashi M; Koyanagi T; Kanagawa K; Hirano T; Seki T; Tsubo S
    Nihon Hinyokika Gakkai Zasshi; 1992 Dec; 83(12):1970-7. PubMed ID: 1474704
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Live donor renal transplantation with low-dose triple immunosuppression.
    Francis DM; Millar RJ; Walker RG; Nicholls K; Powell H; Jones C; Kockelbergh R; Becker G
    Transplant Proc; 1992 Oct; 24(5):2243. PubMed ID: 1413041
    [No Abstract]   [Full Text] [Related]  

  • 40. Predictive value of IgG subclass levels for infectious complications in renal transplant recipients.
    Wieneke H; Otte B; Lang D; Heidenreich S
    Clin Nephrol; 1996 Jan; 45(1):22-8. PubMed ID: 8616953
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.